PPARA and colonic neoplasm: Fibrate drugs, which belong to the class of PPARα agonists, can inhibit triglyceride synthesis by promoting β-oxidation, thereby modulating widely altered lipid signaling in cancer cells and impacting colon cancer survival and proliferation [52].